Staurosporine

目录号：S1421 别名： CGP 41251

Molecular Weight(MW): 466.53

Staurosporine是一种有效的PKC抑制剂，在无细胞试验中作用于PKCα，PKCγ 和PKCη，IC50分别为2 nM，5 nM 和 4 nM，对PKCδ(20 nM)和PKCε(73 nM作用较弱，对PKCζ (1086 nM)的活性很低。同时对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。

规格

价格

库存

购买数量

2mg	RMB 2186.89	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献10篇：

Mol Carcinog, 2018, 57(7):886-895

PubMed: 29566278 ( click the link to review the publication )

Gastroenterology, 2017, 153(5):1429-1443

PubMed: 28764929 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0154932

PubMed: 27183222 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 471(4):528-32

PubMed: 26879140 ( click the link to review the publication )

Exp Clin Endocrinol Diabetes, 2016, 1427:419-30

PubMed: 26849668 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7090-102

PubMed: 25277525 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2013, 304(9):C895-904

PubMed: 23447036 ( click the link to review the publication )

J Biomol Screen, 2013, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39679

PubMed: 22768106 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

客户使用该产品的4个实验数据：

J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.
Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述

靶点

PKCα ^[1] (Cell-free assay)	c-Fgr ^[2] (Cell-free assay)	phosphorylase kinase ^[2] (Cell-free assay)	PKCη ^[1] (Cell-free assay)	PKCγ ^[1] (Cell-free assay)	点击更多
2 nM	2 nM	3 nM	4 nM	5 nM	点击更多

体外研究

Staurosporine 也强抑制HeLa S3细胞，IC50为4 nM。^[1]Staurosporine 也抑制多种其他蛋白激酶，包括PKA, PKG, 磷酸激酶, S6 激酶, 肌球蛋白轻链激酶(MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, 和Syk ， IC50分别为 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, 和 16 nM。^[3] Staurosporine (1 μM) 诱导 PC12细胞90%以上凋亡,这种作用可被过量表达的Bcl-2抑制,或者zVAD-fmk, cycloheximide (10 μM) 及actinomycin D (5 μM)处理也可抑制。相应地, Staurosporine处理，诱导细胞内游离钙水平 [Ca²⁺]_i快速且持久的提升，线粒体活性氧（ROS）的积累,及随后的线粒体功能障碍。^[4]通过caspase-8激活和Bid 分裂，功能性caspase-3的表达可增强Staurosporine诱导MCF7细胞死亡。^[5] 1 μM Staurosporine处理，只部分抑制IL-3刺激的Bcl2 磷酸化，而完全阻断PKC调节的 Bcl2磷酸化。^[6] Staurosporine 诱导人类包皮成纤维细胞AG-1518凋亡,根据溶酶体组织蛋白酶D调节的细胞色素 c释放和 caspase 激活。^[7] 除了激活传统线粒体凋亡通路, Staurosporine触发一种新型内在凋亡通路, 依赖Apaf-1存在时对caspase-9的激活。^[8]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human HeLa cells	NYXKbFYzS3m2b4TvfIlkyqCjc4PhfS=>	M{nWNFQ5KGh?	MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;NHWtNFYh\|ryPLh?=	M3fNelIyOzh6MUmx
human colon cancer cell line (LoVo cells)	MX7Qdo9tcW[ncnH0bY9vKGG\|c3H5		MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKGOxbH;uJINidmOncjDj[YxtKGyrbnWgLGxwXm9iY3XscJMqKHW\|aX7nJG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2u	MYKxNVU6OTVyNR?=
human LoVo cells	Ml;mVJJwdGmoZYLheIlwdiCjc4PhfS=>	NFHIUXk1QCC2bzC3NkBp	MnPRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOb2\vJINmdGy\|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZk>	MWqyNlE5Ojl{OR?=
P19 cells	NH;TPXVHfW6ldHnvckBie3OjeR?=		MoDPTY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgdoVk\XC2b4KgbY4hWDF7IHPlcIx{NCCLQ{WwQVAvODB{IN88UU4>	NUjyNHd2OTV5N{G0NVk>
human BJ cells	NHnIOGdEgXSxdH;4bYPDqGG\|c3H5	NVzFVGF7PzJiaB?=	NUT2S5oxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNidGOnaX6gRW0h[XO\|YYmsJGlEPTB;MD6wNFIh\|ryPLh?=	Mn\lNlI6OjFyOEG=
human HT-29 cells	NEnqVolHfW6ldHnvckBie3OjeR?=	NULPU3dJOiCq	MYnF[oZm[3Rib36gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyb4TlcpRq[WxiaX6gbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiMjDodpMhfXOrbnegTmMuOSC\|dHHpcolv\yCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYm=	MoPYNlE1Ojh\|N{W=
human A549 cells	NYnBNVE4S3m2b4TvfIlkyqCjc4PhfS=>	MUC3NkBp	NHjWSJVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJI1mfGixZB?=	NXriU2VpOTh2OES3O\|U>
human HT-29 cells	NX\5RndiTnWwY4Tpc44h[XO\|YYm=		M2e4dWlvcGmkaYTpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwhcW5iaIXtZY4hUFRvMkmgZ4VtdHNidYPpcochUkNzIHT5[UB{fGGrbnnu[{BjgSCobIXvdoV{[2WwY3WgdIxifGVicnXh[IVzKGG\|c3H5MEBKSzVyPUKuOUBvVQ>?	NX;IUWFvOjF3MUOyPVM>
human HT-29 cells	Mlz0SpVv[3Srb36gZZN{[Xl?	MlK3NkBp	MVHJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiWLUK5JINmdGy\|IHHzd4V{e2WmIILl[JVkfGmxbjDv[kBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDveIVvfGmjbDDh[pRmeiB{IHjyd{BjgSC3c3nu[{BLSzFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGOnbHytZoF{\WRiYYPzZZktKEWFNUC9Nk43KG6PLh?=	NUfybnFDOjF7N{OxNFE>
Sf9 cells	MWHGeY5kfGmxbjDhd5NigQ>?		NHjN[3pKdmirYnn0bY9vKG:oIHj1cYFvKFO7azDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{NCCLQ{WwQVMhdk1w	M{KwV\|E5QDJ\|N{i0
human HUVEC	MnXKVJJwdGmoZYLheIlwdiCjc4PhfS=>	NY\ZdHhvPDhidH:gO\|IhcA>?	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiXVlXDJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[Xl?	MXuyNlE5Ojl{OR?=
P19 cells	M{Lae2Z2dmO2aX;uJIF{e2G7		MXXJcohq[mm2aX;uJI9nKFC{b4TlbY4hU2mwYYPlJGEhcW5iUEG5JINmdGy\|LDDJR\|UxRTRibl2u	NUXiVFdxOTV5N{G0NVk>
Sf9 cells	MoHiSpVv[3Srb36gZZN{[Xl?		Mn7VTY5pcWKrdHnvckBw\iCqdX3hckBHgW5iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJI1qdiCkeTDFUGlUSSCrbjDwdoV{\W6lZTDv[kAyKHWvb3yvUEBCXFB?	MkTVNVc{OTV6NUO=
Sf21 cells	NXv3TGpMTnWwY4Tpc44h[XO\|YYm=		MmLTTY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy\|LDDJR\|UxRTZibl2u	MoHnNVcxQDhyNUm=
human colon carcinoma cell line HCT116	MnLqSpVv[3Srb36gZZN{[Xl?		MlTBR49v[2WwdILheIlwdiC{ZYH1bZJm\CCob4Kg[5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwhdGmwZTDIR3QyOTZuIFnDOVA:PiCwTT6=	MXixOVU{PzN2NR?=
human ST486 cells	MWXQdo9tcW[ncnH0bY9vKGG\|c3H5	M4PHTlQ5KHSxIEeyJIg>	NVLZb2I3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWFQ5PiClZXzsd{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTdibl2u	MYmyNlE5Ojl{OR?=
human MDA-MB-231 cells	M4D5WWN6fG:2b4jpZ:Kh[XO\|YYm=	MoHDO\|IhcA>?	MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKG2ndHjv[EwhT0l3ME23MlEhdk1w	MlLZNVg1QDR5N{W=
P19 cells	MU\GeY5kfGmxbjDhd5NigQ>?		M1LJXGlvcGmkaYTpc44hd2ZiQ4njcIlvNWSncHXu[IVvfCCtaX7hd4UhOSCrbjDQNVkh[2WubIOsJGlEPTB;ODDuUU4>	M{OzSFE2PzdzNEG5
human DLD1 cells	NWG0Z4NbWHKxbHnm[ZJifGmxbjDhd5NigQ>?	Mon4OFguPzJiaB?=	NGTI[GxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTMSFEh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF06KG6PLh?=	MWiyNlE5Ojl{OR?=
insect cells	MWDGeY5kfGmxbjDhd5NigQ>?		M2ruSmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUHntNUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIJ6KEiWUl[sJGlEPTB;MUCgcm0v	MUCxPVE4QTB5Nh?=
V79 MZ cells	M4rieGZ2dmO2aX;uJIF{e2G7		NHy1fJRKdmirYnn0bY9vKG:oIHj1cYFvKGGuZH;zeIVzd26nIIP5cpRp[XOnIHX4dJJme3OnZDDpckBXPzliTWqgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjbHTvd5Rmem:wZTDzfY51cGW\|aYOsJGlEPTB;MUGgcm0v	NWTyWGJDOjR2MkK1NVk>
P19 cells	MojMSpVv[3Srb36gZZN{[Xl?		MXHJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy\|LDDJR\|UxRTF2IH7NMi=>	Mm\ENVU4PzF2MUm=
Sf9 cells	M{OwZ2Z2dmO2aX;uJIF{e2G7	MoO4NlAhdWmwcx?=	NHTJ[YRKdmirYnn0bY9vKG:oIHj1cYFvKE[7bjDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFIxKG2rboOgZpkhTUyLU1GgbY4heHKnc3XuZ4Uhd2ZiMTD1cY9tN0xiQWTQMEBKSzVyPUG1JI5ONg>?	M3HuOlE4OzF3OEWz
human PBMC	MVjGeY5kfGmxbjDhd5NigQ>?	NVH6Umd6OjRiaB?=	M332dXN2eHC{ZYPzbY9vKG:oIFnMNkBxem:mdXP0bY9vKGmwIHj1cYFvKFCETVOgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwQVE3KG6PLh?=	MkTlNVg2QDVyNE[=
human A549 cells	MYHDfZRwfG:6aXRCpIF{e2G7	MlHqOFghcA>?	MmfxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5JEwhUUN3ME2yNEBvVS5?	NYrh[3kyOjV6MkW5N\|Q>
human CEM cells	Mon6R5l1d3SxeHnjxsBie3OjeR?=	NXrJVIh2PzJiaB?=	MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OjNibl2u	M2\qfVIzQTJzMEix
human HeLa cells	M{XJVmN6fG:2b4jpZ:Kh[XO\|YYm=	MVy0PEBp	NXXrWXFpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI2KG6PLh?=	NIP6Nm0zPTh{NUmzOC=>
human PC3 cells	M{G1Z2N6fG:2b4jpZ:Kh[XO\|YYm=	NFO2eJQ1QCCq	Mmq4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmgMEBKSzVyPUOxJI5ONg>?	NYn5SGZROjV6MkW5N\|Q>
human SF268 cells	MkXhR5l1d3SxeHnjxsBie3OjeR?=	NETheoE1QCCq	MmP6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3ME20OEBvVS5?	MVKyNVUyOzJ7NB?=
human MCF7 cells	MU\DfZRwfG:6aXRCpIF{e2G7	M1HN[lQ5KGh?	M4\FPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME21NEBvVS5?	NIWy[XMzOTN6OEG5NS=>
HEK293 cells	M2K5[GN6fG:2b4jpZ:Kh[XO\|YYm=	NX3vUJh4PzJiaB?=	MkXOR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XKJbH:gZZN{[XluIFnDOVA:PTZibl2u	MWqyOFc3OzJ4Mh?=
HUE cells	M1XseWZ2dmO2aX;uJIF{e2G7	MYC5NEBucW6\|	MX3Jcohq[mm2aX;uJI9nKF[HR1\SNkBqdiCKVVWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB1emWjdHXkJIZweiB7MDDtbY5{KGKnZn;y[UBXTUeIIHPoZYxt\W6pZTDifUBGVEmVQTygTWM2OD15MDDuUU4>	NEfNTYwzODF5MEG2Ny=>
human A431 cells	NV23OFJ7S3m2b4TvfIlkyqCjc4PhfS=>	NFz4bXYzPCBiaB?=	MmLER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{Bi\nSncjCyOEBpenNidYPpcochSW6wZYjpckBX\U[LVFOvdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDifUBOXFRiYYPzZZktKEmFNUC9O\|Ahdk1w	NYfkfHhlOjJ3NEGwOVE>
human Jurkat cells	NY\DR3FNWHKxbHnm[ZJifGmxbjDhd5NigQ>?		M1;WSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTmFMOyCneIDy[ZN{cW6pIFnMNk1{fGmvdXzheIVlKGi3bXHuJGp2emujdDDj[YxteyxiSVO1NF04OSCwTT6=	NYrBRXZLOTl2MkeyNFM>
HEK293 cells	MkGxSpVv[3Srb36gZZN{[Xl?		M{DDN2lvcGmkaYTpc44hd2ZiSVytPEBz\WynYYPlJIJ6KEiHS{K5N{Bk\WyuczDlfJBz\XO\|aX7nJHBMSy2kZYThNkwhUUN3ME23O{BvVS5?	MUKxOVc4OTRzOR?=
human KE-97 cells	NUT5O2tZS3m2b4TvfIlkyqCjc4PhfS=>	NXLSd3VFPzJiaB?=	NXLab4QyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0VvOUegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRz\S2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMzFOwG0v	NGTzUJQzPDN{OEK4Ny=>
human CHOK1 cells	Ml;YR5l1d3SxeHnjxsBie3OjeR?=	NXHWc3N6PDhiaB?=	NFqyeGpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEUE:NMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5zMzFOwG0v	MlHlNlE2OTN{OUS=
mouse NIH/3T3 cells	M361RmN6fG:2b4jpZ:Kh[XO\|YYm=	M{\UZ\|k3KGh?	MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6=	M3XDflI1OzZzNUKx
human A2780 cells	NVTpWlV3S3m2b4TvfIlkyqCjc4PhfS=>	NUn2N4pSQTZiaB?=	M1jDcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6=	NYXHV3U2OjR\|NkG1NlE>
human 8505C cells	MnPqR5l1d3SxeHnjxsBie3OjeR?=	NYPzOoxVQTZiaB?=	MnjYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh\|ryPLh?=	NF[5ZpczPDN4MUWyNS=>
human 518A2 cells	MVPDfZRwfG:6aXRCpIF{e2G7	MYC5OkBp	M{jkSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=>	MXGyOFM3OTV{MR?=
human HuH7 cells	MXfDfZRwfG:6aXRCpIF{e2G7	MV63NkBp	MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNlMh\|ryPLh?=	M{XKZlI1OzJ6Mkiz
FL5.12-Akt1 cells	MXnQdo9tcW[ncnH0bY9vKGG\|c3H5		MnnmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDGUFUvOTJvQXv0NUBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9NE4zQSEQvF2u	MmTZNVY1ODN4Mk[=
human MiaPaCa-2 cells	MmLSVJJwdGmoZYLheIlwdiCjc4PhfS=>		MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2rYWDhR4EuOiClZXzsd{whUUN3ME2wMlM4KM7:TT6=	NESwclMyPjRzM{e4NC=>
human BGC823 cells	M37qXWN6fG:2b4jpZ:Kh[XO\|YYm=	NFTZN\|Y4OiCq	NFnCPZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDT0N6MkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRz\S2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5\|ODFOwG0v	NHnoUWwzPDN{OEK4Ny=>
human MCF7 cells	M{LLU2N6fG:2b4jpZ:Kh[XO\|YYm=	MX:5OkBp	M1HzbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgPVYhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlQh\|ryPLh?=	NWfyb2h7OjR\|NkG1NlE>
human A549 cells	M3vzd2N6fG:2b4jpZ:Kh[XO\|YYm=	NH\nT2o6PiCq	MmLhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyPUCuOkDPxE1w	NH\o[FkzPDN4MUWyNS=>
HEK293 cells	MYTDfZRwfG:6aXRCpIF{e2G7		MoG3R5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy\|LDDFR\|UxRTJizszNMi=>	NWHKe4c1OjV\|MU[zNVc>
human Raji cells	MWPDfZRwfG:6aXRCpIF{e2G7		NUTvdoQ{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6=	NHTCWJkzPTNzNkOxOy=>
human HepG2 cells	M1e2XmN6fG:2b4jpZ:Kh[XO\|YYm=		M2fVTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{NCCHQ{WwQVIh\|ryPLh?=	NXHyTXZkOjV\|MU[zNVc>
human BJ cells	MkTPR5l1d3SxeHnjxsBie3OjeR?=		MmfXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOsJGVEPTB;MjFOwG0v	NHTDVJczPTNzNkOxOy=>
human U937 cells	MWHDfZRwfG:6aXRCpIF{e2G7		MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzMEBKSzVyPUKg{txONg>?	NUPvfohZOTdyOEiwOlc>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Akt / Akt / PARP /Cleaved PARP; PubMed: 24174874 Int J Nanomedicine Western blot analysis for Akt, P-Akt, and cleaved poly(ADP-ribose) polymerase. U87 cells were incubated with 200 nM, 10 nM, and 0.1 nM of staurosporine encapsulated in liposomes and staurosporine for 32 hours. FAK / RIP; PubMed: 15121855 Mol Cell Biol Western blot (WB) analysis of BT-20 and BT-474 lysates treated with staurosporine (200 nM). Control cells were treated with dimethyl sulfoxide for 18 h. Ambra1; PubMed: 24587252 PLoS One SW620 cells treated with various doses of staurosporine for 6 h. Ambra1 levels were measured by Western blot.	24174874 15121855 24587252
Growth inhibition assay	Cell viability; PubMed: 25215174 Oxid Med Cell Longev Staurosporine reduces cerebellar astrocytes viability. (a) Cerebellar astrocytes were treated with staurosporine 0.1 μM, 0.25 μM, and 0.5 μM for 24 h and the cell viability was measured by MTT transformation. (b) Cerebellar astrocytes were treated with staurosporine 0.5 μM for 6, 12, and 24 h and the cell viability was measured by MTT transformation. Data are presented as mean ± SEM of four independent experiments. ∗ is significantly different from control (P < 0.05).	25215174
Immunofluorescence	Tubulin / Actin; PubMed: 25215174 Oxid Med Cell Longev Morphological changes of astrocytes induced by St are evidenced by the rearrangement of cytoskeletal proteins. Astrocytes were treated with St (0.5 μM) for 12 hours and then were labelled with rhodamine-phalloidin or immunostained for tubulin. Representative images of phase contrast, rhodamine-phalloidin, and tubulin are shown in control and St treated astrocytes. Scale bar represents 50 μm. Phalloidin / Type II collagen; PubMed: 22684244 Exp Mol Med Cell were cultured in the absence (a-f) or presence of staurosporine (STSN, 5 × 10-9M) or cytochalasin D (CD, 1 µg/ml) for 1 (upper panel) or 2 (lower panel) days at low density and stained for F-actin (Phalloidin) and type II collagen (Type II). STSN: Staurosporine. Pyk2; PubMed: 19880522 J Biol Chem Pyk2 translocates to the nucleus upon staurosporine addition to ID8 cells. Confocal immunofluorescent analysis of endogenous Pyk2 upon DMSO (control) or 1 μm staurosporine addition for 2 h. The scale bar is 10 μm. Annexin; PubMed: 15140398 Neoplasia Induction of apoptosis with staurosporine resulting in activation of the ICE-NIRF probe. Gli36 cells were treated with 50 µM staurosporine for 24 hours (A-C) or with the same percentage of DMSO (0.01%) to which experimental wells were exposed (D-488nm laser, E-633nm laser and F-bright field). To examine the role of caspase-1 in staurosporine-induced apoptosis and probe activation, cells were coincubated in caspase-1 inhibitor (10 µM) and staurosporine (G-I). Staurosporine induces apoptosis, indicated by the positive annexin staining viewed with the 488-nm laser (A), which colocalized with activated probe viewed with the 633-nm laser (B). Coincubation of the caspase-1 inhibitor with staurosporine did not completely block apoptosis, indicated by the relatively higher number of apoptotic cells stained with annexin (G), as those that activated the probe (H). Magnification, x 40; scale bar, 50 µM. cleaved-caspase 3; PubMed: 19840952 Cardiovasc Res Representative images (×1000 magnification) showing vehicle treated (C) and staurosporine treated (D) cells stained with anti-cleaved caspase 3 antibody and DAPI. FAK 4.47; PubMed: 15121855 Mol Cell Biol BT-20 or BT-474 cell culture were plated on six-well plates and were treated with staurosporine (200 nM) after 24 h. After 6 h of treatment, cells were immunostained with anti-FAK 4.47 antibody (white arrowheads mark some focal adhesions).	25215174 22684244 19880522 15140398 19840952 15121855

体内研究

在局部贫血前，使用Staurosporine(0.1-10 ng)预处理局部贫血沙鼠和大鼠模型，可防止神经元损伤，这种作用存在剂量依赖性，说明CAl锥体细胞死亡涉及PKC。^[2]

激酶实验： ^[1]	+ 展开 Enzyme assay and binding assay: Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl₂, 1.25 nmol of [γ-³²]ATP (5-10 × 10⁴ cpm/nmol) and 5 μg of partially purified enzyme. The binding of [³H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC1₂, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [³H]PDBu (l-3 × 10⁴ cpm/pmol) and 10 μL of various amounts of Staurosporine.
细胞实验：^[4]	+ 展开 Cell lines: PC12 Concentrations: 溶于DMSO,终浓度为1 μM Incubation Time: ~32 小时 Method: 使用Staurosporine处理细胞32小时。细胞在4%多聚甲醛中混合，然后使用DNA结合染料Hoechst 33342染色。在荧光照明下观察细胞，测定凋亡细胞百分数。 (Only for Reference)
动物实验：^[2]	+ 展开 Animal Models: 短暂局部贫血的雄性Mongolian沙鼠或雄性 Wistar大鼠 Formulation: 溶于DMSO,然后在盐水中稀释 Dosages: ~10 ng Administration: 定向处理到海马双边CA₁子域 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	4 mg/mL (8.57 mM)
	Water	Insoluble
	Ethanol	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Staurosporine SDF

分子量	466.53
化学式	C₂₈H₂₆N₄O₃
CAS号	62996-74-1
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	CGP 41251

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00301938	Completed	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Acute Promyelocytic Leukemia (M3)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Myelodysplastic/Myeloproliferative Neoplasms\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|T-cell Adult Acute Lymphoblastic Leukemia\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Adult Acute Myeloid Leukemia	National Cancer Institute (NCI)	December 2005	Phase 1
NCT00301938	Completed	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Acute Promyelocytic Leukemia (M3)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Myelodysplastic/Myeloproliferative Neoplasms\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|T-cell Adult Acute Lymphoblastic Leukemia\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Adult Acute Myeloid Leukemia	National Cancer Institute (NCI)	December 2005	Phase 1
NCT00098956	Completed	Extensive Stage Small Cell Lung Cancer\|Recurrent Small Cell Lung Cancer	National Cancer Institute (NCI)	January 2005	Phase 2
NCT00098956	Completed	Extensive Stage Small Cell Lung Cancer\|Recurrent Small Cell Lung Cancer	National Cancer Institute (NCI)	January 2005	Phase 2
NCT00082017	Terminated	Lymphoma Large-Cell Ki-1\|Lymphoma T-Cell	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	April 5 2004	Phase 2
NCT00082017	Terminated	Lymphoma Large-Cell Ki-1\|Lymphoma T-Cell	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	April 5 2004	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

Staurosporine

客户使用Selleck该产品发表文献10篇：

客户使用该产品的4个实验数据：

产品安全说明书

PKC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Staurosporine SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

PKC Signaling Pathway Map

相关PKC产品